Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects

References

• Diamond A. Executive functions. Annu Rev Psychol. 2013;64(1):135–168.
   PubMed Web of Science ®Google Scholar
• Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. JAD. 2012;32(4):793–887.
   Google Scholar
• Steiner H, Van Waes V. Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol. 2013;100:60–80.
   PubMed Web of Science ®Google Scholar
• Reed SK. Cognition: theories and applications. 9th ed. Belmont, CA: Jon-David Hague; 2013.
   Google Scholar
• Siva J. Nootropics and smart drugs: super boost your mental alertness, cognition, memory, focus, creativity and mood. Philadelphia, PA: BookBaby; 2012.
   Google Scholar
• Giurgea C. The “nootropic” approach to the pharmacology of the integrative activity of the brain 1, 2. Cond Reflex 1973;8(2):108–115.
   PubMedGoogle Scholar
• Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s pharmacology. 8th ed. London: Churchill Livingstone; 2016.
   Google Scholar
• Katzung BG, Trevor AJ. Basic & clinical pharmacology. New York, NY: McGraw-Hill; 2018.
   Google Scholar
• Warner CB, Ottman AA, Brown JN. The role of atomoxetine for Parkinson disease-related executive dysfunction: a systematic review. J Clin Psychopharmacol. 2018;38(6):627–631.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. Metabolomics of methylphenidate and ethylphenidate: implications in pharmacological and toxicological effects. Eur J Drug Metab Pharmacokinet. 2017;42(1):11–16.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. [Licit and ilicit uses of medicines]. Acta Med Port 2014;27(6):755–766.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. Metabolomics of cocaine: implications in toxicity. Toxicol Mech Methods. 2015;25(6):494–500.
   PubMed Web of Science ®Google Scholar
• McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016;71:294–312.
   PubMed Web of Science ®Google Scholar
• Kasabova-Angelova A, Tzankova D, Mitkov J, et al. Xanthine derivatives as agents affecting non-dopaminergic neuroprotection in Parkinson`s disease. Curr Med Chem 2018. doi: 10.2174/0929867325666180821153316. In press.
   PubMed Web of Science ®Google Scholar
• Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(Suppl):S77–S88.
   PubMedGoogle Scholar
• Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;3:Cd000207.
   PubMedGoogle Scholar
• Ferreira GC, McKenna MC. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017;42(6):1661–1675.
   PubMed Web of Science ®Google Scholar
• Augustyniak J, Lenart J, Zychowicz M, Stepien PP, Buzanska L. Mitochondrial biogenesis and neural differentiation of human iPSC is modulated by idebenone in a developmental stage-dependent manner. Biogerontology. 2017;18(4):665–677.
   PubMed Web of Science ®Google Scholar
• Dolce G, Cecconi V, Zamponi A, Zylberman R, Maggi L, Battaglia A. Methodological approach to the clinical evaluation of nootropic drugs. Berlin, Heidelberg, Germany: Springer Berlin, Heidelberg; 1985:215–222.
   Google Scholar
• Castaldi S, Gelatti U, Orizio G, et al. Use of cognitive enhancement medication among northern Italian university students. J Addict Med. 2012;6(2):112–117.
   PubMed Web of Science ®Google Scholar
• Carton L, Cabe N, Menard O, et al. Pharmaceutical cognitive doping in students: a chimeric way to get-a-head?] Therapie. 2018;73(4):319–329.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S. An overview of the clinical uses, pharmacology, and safety of modafinil. ACS Chem Neurosci. 2018;9(2):151–158.
   PubMed Web of Science ®Google Scholar
• Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139.
   PubMed Web of Science ®Google Scholar
• Kalaba P, Aher NY, Ilic M, et al. Heterocyclic analogues of modafinil as novel, atypical dopamine transporter inhibitors. J Med Chem. 2017;60(22):9330–9348.
   PubMed Web of Science ®Google Scholar
• Loland CJ, Mereu M, Okunola OM, et al. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012;72(5):405–413.
   PubMed Web of Science ®Google Scholar
• Robertson P, Jr., Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123–137.
   PubMed Web of Science ®Google Scholar
• Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008;68(13):1803–1839.
   PubMed Web of Science ®Google Scholar
• Donovan JL, Malcolm RJ, Markowitz JS, DeVane CL. Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. Ther Drug Monit. 2003;25(2):197–202.
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol. 1999;39(3):281–288.
   PubMed Web of Science ®Google Scholar
• Dowling G, Kavanagh PV, Talbot B, et al. Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog. Drug Test Analysis. 2017;9(3):518–528.
   PubMed Web of Science ®Google Scholar
• Keighron JD, Quarterman JC, Cao J, et al. Effects of (R)-modafinil and modafinil analogues on dopamine dynamics assessed by voltammetry and microdialysis in the mouse nucleus accumbens shell. ACS Chem Neurosci. 2019;10(4):2012–2021.
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38(3):276–282.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Donovan JL, et al. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol. 2008;578(2–3):148–158.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig. 2009;29(9):601–612.
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC. Wake-promoting pharmacotherapy for psychiatric disorders. Curr Psychiatry Rep. 2014;16(12):524.
   PubMed Web of Science ®Google Scholar
• Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos. 2000;28(6):664–671.
   PubMed Web of Science ®Google Scholar
• Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39(1):30–40.
   PubMed Web of Science ®Google Scholar
• Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin. 2006;22(1):159–167.
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Spencer CM. Modafinil. CNS Drugs. 1998;9(4):311–324.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang X, Yang S, et al. Doping control analysis for adrafinil and its major metabolites in human urine. Rapid Commun Mass Spectrom. 2009;23(11):1592–1600.
   PubMed Web of Science ®Google Scholar
• Chatterjie N, Stables JP, Wang H, Alexander GJ. Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity. Neurochem Res. 2004;29(8):1481–1486.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P, Jr., Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61–74.
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P. Jr., Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and aripiprazole in healthy adults. Pharmacopsychiatry. 2015;48(4–5):170–175.
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Hellriegel ET, Youakim JM, Yang R, Robertson P. Jr., Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study. J Clin Pharmacol. 2012;52(9):1399–1409.
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P. Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. Clin Drug Investig. 2015;35(11):725–733.
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P. Jr., Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. Clin Ther. 2015;37(2):325–337.
   PubMed Web of Science ®Google Scholar
• Robertson P, Jr., Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42(2):205–214.
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012;100(4):801–810.
   PubMed Web of Science ®Google Scholar
• Gonzalez B, Torres OV, Jayanthi S, et al. The effects of single-dose injections of modafinil and methamphetamine on epigenetic and functional markers in the mouse medial prefrontal cortex: potential role of dopamine receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:222–234.
   PubMed Web of Science ®Google Scholar
• Jones SR, Gainetdinov RR, Hu XT, et al. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci. 1999;2(7):649–655.
   PubMed Web of Science ®Google Scholar
• Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci. 2000;12(1):19–26.
   PubMed Web of Science ®Google Scholar
• Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787–1794.
   PubMed Web of Science ®Google Scholar
• Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009;63(8):698–704.
   PubMed Web of Science ®Google Scholar
• Westerink BH, Tuntler J, Damsma G, Rollema H, de Vries JB. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedeberg's Arch Pharmacol. 1987;336(5):502–507.
   Google Scholar
• Mereu M, Chun LE, Prisinzano TE, Newman AH, Katz JL, Tanda G. The unique psychostimulant profile of (±)-modafinil: investigation of behavioral and neurochemical effects in mice. Eur J Neurosci. 2017;45(1):167–174.
   PubMed Web of Science ®Google Scholar
• Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem. 2006;98(2):408–419.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacol. 2008;33(7):1477–1502.
   PubMed Web of Science ®Google Scholar
• Perugi G, Vannucchi G, Bedani F, Favaretto E. Use of Stimulants in Bipolar Disorder. Curr Psychiatry Rep. 2017;19(1):7.
   PubMed Web of Science ®Google Scholar
• Cao J, Prisinzano TE, Okunola OM, et al. Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues. ACS Med Chem Lett. 2011;2(1):48–52.
   Google Scholar
• Cao J, Slack RD, Bakare OM, et al. Novel and high affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) analogues as atypical dopamine transporter inhibitors. J Med Chem. 2016;59(23):10676–10691.
   PubMed Web of Science ®Google Scholar
• Reith ME, Blough BE, Hong WC, et al. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend. 2015;147:1–19.
   PubMed Web of Science ®Google Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(04):554–566.
   PubMedGoogle Scholar
• Ishizuka T, Murotani T, Yamatodani A. Action of modafinil through histaminergic and orexinergic neurons. Vitam Horm. 2012;89:259–278.
   PubMed Web of Science ®Google Scholar
• Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128–14133.
   PubMed Web of Science ®Google Scholar
• Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998;241(2–3):95–98.
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20(22):8620–8628.
   PubMed Web of Science ®Google Scholar
• de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport. 2001;12(16):3533–3537.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Muller F, Dolder PC, et al. Comparative effects of methylphenidate, modafinil, and MDMA on response inhibition neural networks in healthy subjects. Int J Neuropsychopharmacol. 2017;20(9):712–720.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS. Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science. 2008;322(5908):1700–1702.
   PubMed Web of Science ®Google Scholar
• Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38(10):971–978.
   PubMed Web of Science ®Google Scholar
• Hellriegel ET, Arora S, Nelson M, Robertson P. Jr., Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J Clin Pharmacol. 2001;41(8):895–904.
   PubMed Web of Science ®Google Scholar
• Hellriegel ET, Arora S, Nelson M, Robertson P. Jr., Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol. 2002;42(4):450–460.
   PubMed Web of Science ®Google Scholar
• Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17(suppl_8):S107–S112.
   PubMed Web of Science ®Google Scholar
• Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1(1):49–61.
   PubMedGoogle Scholar
• Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev. 2014;66(1):193–221.
   PubMed Web of Science ®Google Scholar
• Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561–569.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord. 2009;11 (Suppl 2):123–137.
   PubMedGoogle Scholar
• Anaclet C, Ferrari L, Arrigoni E, et al. The GABAergic parafacial zone is a medullary slow wave sleep-promoting center. Nat Neurosci. 2014;17(9):1217–1224.
   PubMed Web of Science ®Google Scholar
• Anaclet C, Griffith K, Fuller PM. Activation of the GABAergic parafacial zone maintains sleep and counteracts the wake-promoting action of the psychostimulants armodafinil and caffeine. Neuropsychopharmacol. 2018;43(2):415–425.
   PubMed Web of Science ®Google Scholar
• Yan WW, Yao LH, Chen C, et al. Effects of modafinil on behavioral learning and hippocampal synaptic transmission in rats. Int Neurourol J. 2015;19(4):220–227.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, Oʼconnor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport. 1997;8(13):2883–2887.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett. 1998;253(2):135–138.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, Tanganelli S. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology. 1999;20(4):346–356.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res. 2002;68(1):107–112.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology. 2000;39(11):1974–1983.
   PubMed Web of Science ®Google Scholar
• Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nss. 2017;9:127–133.
   Web of Science ®Google Scholar
• Urbano FJ, Bisagno V, Garcia-Rill E. Arousal and drug abuse. Behav Brain Res. 2017;333:276–281.
   PubMed Web of Science ®Google Scholar
• Lin JS, Roussel B, Gaspar A, et al. The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons. Sleep Med. 2018;49:40–52.
   PubMed Web of Science ®Google Scholar
• Mereu M, Bonci A, Newman AH, Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berl). 2013;229(3):415–434.
   PubMed Web of Science ®Google Scholar
• Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord. 2006;95(1–3):111–114.
   PubMed Web of Science ®Google Scholar
• Lankford DA. Armodafinil: a new treatment for excessive sleepiness. Expert Opin Investig Drugs. 2008;17(4):565–573.
   PubMed Web of Science ®Google Scholar
• Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591(2):319–326.
   PubMed Web of Science ®Google Scholar
• Stone EA, Cotecchia S, Lin Y, Quartermain D. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse. 2002;46(4):269–270.
   PubMed Web of Science ®Google Scholar
• Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep. 1995;18(10):817–826.
   PubMed Web of Science ®Google Scholar
• Pal China S, Pal S, Chattopadhyay S, et al. The wakefulness promoting drug Modafinil causes adenosine receptor-mediated upregulation of receptor activator of nuclear factor kappaB ligand in osteoblasts: negative impact of the drug on peak bone accrual in rats. Toxicol Appl Pharmacol. 2018;348:22–31.
   PubMed Web of Science ®Google Scholar
• FDA. Medication guide PROVIGIL (Modafinil) tablets. North Wales: Cephalon, Inc.; 2015 (1998–2015).
   Google Scholar
• Greenblatt K, Adams N. Modafinil. Treasure Island: StatPearls Publishing LLC; 2019.
   Google Scholar
• Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:175628641987562–1756286419875622.
   Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(10):43.
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Modafinil/armodafinil in the treatment of narcolepsy. In: Goswami M, Thorpy MJ and Pandi-Perumal SR eds. Narcolepsy: a clinical guide. Cham, Switzerland: Springer International Publishing; 2016:331–339.
   Google Scholar
• FDA. Medication guide NUVIGIL (Armodafinil) tablets. North Wales: Cephalon, Inc.; 2017 (2007–2017).
   Google Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39–57.
   PubMed Web of Science ®Google Scholar
• Schwartz JR, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med. 2003;4(1):43–49.
   PubMed Web of Science ®Google Scholar
• Kaser M, Deakin JB, Michael A, et al. Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(2):115–122.
   PubMedGoogle Scholar
• DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87–90.
   PubMed Web of Science ®Google Scholar
• DeBattista C. Executive dysfunction in major depressive disorder. Expert Rev Neurother. 2005;5(1):79–83.
   PubMedGoogle Scholar
• Dell'Osso B, Ketter TA. Use of adjunctive stimulants in adult bipolar depression. Int J Neuropsychopharm. 2013;16(1):55–68.
   PubMed Web of Science ®Google Scholar
• Dell'osso B, Timtim S, Hooshmand F, et al. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. J Affect Disord. 2013;150(1):130–135.
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Ketter TA, Cremaschi L, Spagnolin G, Altamura AC. Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression. Curr Psychiatry Rep. 2013;15(8):378–378.
   PubMed Web of Science ®Google Scholar
• Andrade C, Kisely S, Monteiro I, Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015;60:14–21.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2011;130(1–3):106–113.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009;70(12):1674–1680.
   PubMed Web of Science ®Google Scholar
• Kane JM, D’Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry. 2010;71(11):1475–1481.
   PubMed Web of Science ®Google Scholar
• Lohr JB, Liu L, Caligiuri MP, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Schizoph Res. 2013;150(1):289–296.
   PubMed Web of Science ®Google Scholar
• Lillicrap T, Krishnamurthy V, Attia J, et al. Modafinil in debilitating fatigue after stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial. Trials 2016;17(1):410–410.
   PubMedGoogle Scholar
• Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer J-P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009;70(1):104–112.
   PubMed Web of Science ®Google Scholar
• Wittkampf LC, Arends J, Timmerman L, Lancel M. A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol. 2012;2(3):115–125.
   PubMedGoogle Scholar
• Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance–a review of abuse liability issues. Ann Clin Psychiatry. 2004;16(2):101–109.
   PubMedGoogle Scholar
• Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013;(9):Cd009695.
   PubMed Web of Science ®Google Scholar
• Karila L, Reynaud M. Therapeutic approaches to cocaine addiction. Rev Prat. 2009;59(6):830–834.
   PubMedGoogle Scholar
• Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S. Modafinil treatment of cocaine dependence: a systematic review and meta-analysis. Subst Use Misuse. 2017;52(10):1292–1306.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am. 2012;35(2):425–439.
   PubMed Web of Science ®Google Scholar
• Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci. 2003;1003(1):328–345.
   PubMedGoogle Scholar
• Kampman KM, Lynch KG, Pettinati HM, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend. 2015;155:105–110.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009;104(1–2):133–139.
   PubMed Web of Science ®Google Scholar
• Morgan PT, Angarita GA, Canavan S, et al. Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. Drug Alcohol Depend. 2016;160:49–56.
   PubMed Web of Science ®Google Scholar
• Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT. Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry. 2010;167(3):331–340.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Bi GH, Yang HJ, et al. The novel modafinil analog, JJC8-016, as a potential cocaine abuse pharmacotherapeutic. Neuropsychopharmacol. 2017;42(9):1871–1883.
   PubMed Web of Science ®Google Scholar
• Lapid MI, Kuntz KM, Mason SS, et al. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with lewy bodies: a pilot study. Dement Geriatr Cogn Disord. 2017;43(5–6):269–280.
   PubMed Web of Science ®Google Scholar
• Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–742.
   PubMed Web of Science ®Google Scholar
• Scoriels L, Barnett JH, Murray GK, et al. Effects of modafinil on emotional processing in first episode psychosis. Biol Psychiatry. 2011;69(5):457–464.
   PubMed Web of Science ®Google Scholar
• Scoriels L, Barnett JH, Soma PK, Sahakian BJ, Jones PB. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology (Berl). 2012;220(2):249–258.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Waters AJ, Mooney M. Modafinil and nicotine interactions in abstinent smokers. Hum Psychopharmacol Clin Exp. 2008;23(1):21–30.
   PubMed Web of Science ®Google Scholar
• Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite. 2004;42(2):185–195.
   PubMed Web of Science ®Google Scholar
• Martin CA, Lile J, Guenthner G, Anestis JC, Batten SR, Kelly TH. Behavioral effects of modafinil and nicotine, alone and in combination, in tobacco-deprived young adult smokers. J Clin Psychopharmacol. 2014;34(2):278–281.
   PubMed Web of Science ®Google Scholar
• Schnoll RA, Wileyto EP, Pinto A, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008;98(1–2):86–93.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Shamasunder HK, et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer. 2015;23(6):1503–1512.
   PubMed Web of Science ®Google Scholar
• Davis J, Ahlberg FM, Berk M, Ashley DM, Khasraw M. Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol. 2013;13(1):153.
   PubMedGoogle Scholar
• Joly F, Rigal O, Noal S, Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 2011;20(12):1251–1258.
   PubMed Web of Science ®Google Scholar
• Conley CC, Kamen CS, Heckler CE, et al. Modafinil moderates the relationship between cancer-related fatigue and depression in 541 patients receiving chemotherapy. J Clin Psychopharmacol. 2016;36(1):82–85.
   PubMed Web of Science ®Google Scholar
• Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010;116(14):3513–3520.
   PubMed Web of Science ®Google Scholar
• Morrow GR, Gillies LJ, Hickok JT, Roscoe JA, Padmanaban D, Griggs JJ. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed. J Clin Oncol. 2005;23(16_suppl):8012–8012.
   PubMed Web of Science ®Google Scholar
• Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009;115(12):2605–2616.
   PubMed Web of Science ®Google Scholar
• Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med. 2009;23(8):731–738.
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Garland SN, Heckler CE, et al. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 2015;33(2):165–171.
   PubMed Web of Science ®Google Scholar
• Peoples AR, Garland SN, Perlis ML, et al. Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial. J Cancer Surviv. 2017;11(3):401–409.
   PubMed Web of Science ®Google Scholar
• Garland SN, Roscoe JA, Heckler CE, et al. Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. Sleep Med. 2016;20:18–24.
   PubMed Web of Science ®Google Scholar
• Heckler CE, Garland SN, Peoples AR, et al. Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. Support Care Cancer. 2016;24(5):2059–2066.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Revirajan N, Waubant E. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemp Clin Trials. 2018;64:67–76.
   PubMed Web of Science ®Google Scholar
• Shangyan H, Kuiqing L, Yumin X, Jie C, Weixiong L. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2018;19:85–89.
   PubMed Web of Science ®Google Scholar
• Ford-Johnson L, DeLuca J, Zhang J, Elovic E, Lengenfelder J, Chiaravalloti ND. Cognitive effects of modafinil in patients with multiple sclerosis: a clinical trial. Rehabil Psychol. 2016;61(1):82–91.
   PubMed Web of Science ®Google Scholar
• Miller P, Soundy A. The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis. J Neurol Sci. 2017;381:41–54.
   PubMed Web of Science ®Google Scholar
• Yang TT, Wang L, Deng XY, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;380:256–261.
   PubMed Web of Science ®Google Scholar
• Kuan YC, Wu D, Huang KW, et al. Effects of modafinil and armodafinil in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Clin Ther. 2016;38(4):874–888.
   PubMed Web of Science ®Google Scholar
• Lavault S, Dauvilliers Y, Drouot X, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med. 2011;12(6):550–556.
   PubMed Web of Science ®Google Scholar
• Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat. 2007;3(3):293–301.
   PubMedGoogle Scholar
• Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6):e777–784.
   PubMed Web of Science ®Google Scholar
• Kotagal S. Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev. 2018;25:19–24.
   PubMed Web of Science ®Google Scholar
• Holfinger S, Roy A, Schmidt M. Stevens-Johnson syndrome after armodafinil use. J Clin Sleep Med. 2018;14(05):885–887.
   PubMedGoogle Scholar
• Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(01):137–147.
   PubMedGoogle Scholar
• Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311–320.
   PubMed Web of Science ®Google Scholar
• Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D. Modafinil elicits sympathomedullary activation. Hypertension. 2005;45(4):612–618.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148–1154.
   PubMed Web of Science ®Google Scholar
• Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol. 2009;23(6):660–671.
   PubMed Web of Science ®Google Scholar
• Amar J, Lieber A, Montastruc F, Bagheri H, Pathak A, Montastruc JL. Arterial hypertension and resistance to antihypertensive treatment: a new adverse drug reaction with modafinil. Therapie. 2013;68(1):53–54.
   PubMed Web of Science ®Google Scholar
• Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6(5):458–466.
   PubMed Web of Science ®Google Scholar
• Kinslow CJ, Shapiro SD, Grunebaum MF, Miller EC. Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: case report and review of the literature. J Neurol Sci. 2018;393:1–3.
   PubMed Web of Science ®Google Scholar
• Oskooilar N. A case of premature ventricular contractions with modafinil. Am J Psychiatry. 2005;162(10):1983–1984.
   PubMed Web of Science ®Google Scholar
• Rasetti R, Mattay VS, Stankevich B, et al. Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacol. 2010;35(10):2101–2109.
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res. 2017;84:292–300.
   PubMed Web of Science ®Google Scholar
• Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003;70(1):29–37.
   PubMed Web of Science ®Google Scholar
• Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009;104(2):224–233.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl). 2018;235(2):467–479.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015;181:87–91.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Muller F, Dolder PC, et al. Acute effects of methylphenidate, modafinil, and MDMA on negative emotion processing. Int J Neuropsychopharmacol. 2018;21(4):345–354.
   PubMed Web of Science ®Google Scholar
• Ooi T, Wong SH, See B. Modafinil as a stimulant for military aviators. Aerosp Med Hum Perform. 2019;90(5):480–483.
   PubMed Web of Science ®Google Scholar
• Bisagno V, Gonzalez B, Urbano FJ. Cognitive enhancers versus addictive psychostimulants: the good and bad side of dopamine on prefrontal cortical circuits. Pharmacol Res. 2016;109:108–118.
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat. 2012;43(3):303–312.
   PubMed Web of Science ®Google Scholar
• McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat. 2008;35(3):334–342.
   PubMed Web of Science ®Google Scholar
• Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol. 2010;18(5):395–408.
   PubMed Web of Science ®Google Scholar
• Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol. 2007;15(2):123–133.
   PubMed Web of Science ®Google Scholar
• Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl). 1996;126(4):286–292.
   PubMed Web of Science ®Google Scholar
• Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol. 2002;13(2):105–115.
   PubMed Web of Science ®Google Scholar
• Malcolm R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict. 2002;11(3):247–249.
   PubMed Web of Science ®Google Scholar
• Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl). 2002;161(4):387–395.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol. 1996;306(1–3):33–39.
   PubMed Web of Science ®Google Scholar
• Shuman T, Cai DJ, Sage JR, Anagnostaras SG. Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction. Behav Brain Res. 2012;235(2):105–112.
   PubMed Web of Science ®Google Scholar
• Wuo-Silva R, Fukushiro DF, Hollais AW, et al. Modafinil induces rapid-onset behavioral sensitization and cross-sensitization with cocaine in mice: implications for the addictive potential of modafinil. Front Pharmacol. 2016;7:420.
   PubMed Web of Science ®Google Scholar
• Wuo-Silva R, Fukushiro DF, Borcoi AR, et al. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol. 2011;16(4):565–579.
   PubMed Web of Science ®Google Scholar
• Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000;14(1):53–60.
   PubMed Web of Science ®Google Scholar
• Kate N, Grover S, Ghormode D. Dependence on supratherapeutic doses of modafinil: a case report. Prim Care Companion CNS Disord. 2012;14(5):PCC.11l01333.
   PubMedGoogle Scholar
• Krishnan R, Chary KV. A rare case modafinil dependence. J Pharmacol Pharmacother. 2015;6(1):49–50.
   PubMed Web of Science ®Google Scholar
• Dhillon R, Wu X, Bastiampillai T, Tibrewal P. Could modafinil be a drug of dependence? Aust N Z J Psychiatry. 2015;49(5):485–486.
   PubMedGoogle Scholar
• Swapnajeet S, Bn S, Gourav G. Modafinil dependence and hypersexuality: a case report and review of the evidence. Clin Psychopharmacol Neurosci. 2016;14(4):402–404.
   PubMed Web of Science ®Google Scholar
• Jerry JM, Shirvani N, Dale R. Addiction to armodafinil and modafinil presenting with paranoia. J Clin Psychopharmacol. 2016;36(1):98–100.
   PubMed Web of Science ®Google Scholar
• Hermant JF, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl). 1991;103(1):28–32.
   PubMed Web of Science ®Google Scholar
• Tseng YL, Uralets V, Lin CT, Kuo FH. Detection of modafinil in human urine by gas chromatography-mass spectrometry. J Pharm Biomed Anal. 2005;39(5):1042–1045.
   PubMed Web of Science ®Google Scholar
• Caglayan MG, Sheykhi S, Mosca L, Anzenbacher P. Fluorescent zinc and copper complexes for detection of adrafinil in paper-based microfluidic devices. Chem Commun. 2016;52(53):8279–8282.
   PubMed Web of Science ®Google Scholar
• World Anti-Doping Code (WADA). Prohibited list January 2020. The World Anti-Doping Code: International Standart, Montreal; 2020.
   Google Scholar
• Deventer K, Roels K, Delbeke FT, Van Eenoo P. Prevalence of legal and illegal stimulating agents in sports. Anal Bioanal Chem. 2011;401(2):421–432.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Bell DG. Effects of acute modafinil ingestion on exercise time to exhaustion. Med Sci Sports Exerc. 2004;36(6):1078–1082.
   PubMed Web of Science ®Google Scholar
• Dubey S, Ahi S, Reddy IM, Kaur T, Beotra A, Jain S. A novel study of screening and confirmation of modafinil, adrafinil and their metabolite modafinilic acid under EI-GC-MS and ESI-LC-MS-MS ionization. Indian J Pharmacol. 2009;41(6):278–283.
   PubMedGoogle Scholar
• Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865–1881.
   PubMed Web of Science ®Google Scholar
• Sahakian BJ, Morein-Zamir S. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. Lancet Psychiatry. 2015;2(4):357–362.
   PubMed Web of Science ®Google Scholar
• Franke AG, Bagusat C, Rust S, Engel A, Lieb K. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2014;264(S1):83–90.
   PubMedGoogle Scholar
• Eickenhorst P, Vitzthum K, Klapp BF, Groneberg D, Mache S. Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs. J Psychoactive Drugs. 2012;44(5):418–427.
   PubMed Web of Science ®Google Scholar
• Partridge B, Bell S, Lucke J, Hall W. Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 2013;32(3):295–302.
   PubMed Web of Science ®Google Scholar
• Maier LJ, Liakoni E, Schildmann J, Schaub MP, Liechti ME. Swiss University students' attitudes toward pharmacological cognitive enhancement. PLoS One. 2015;10(12):e0144402.
   PubMed Web of Science ®Google Scholar
• Dursun S, Dunn M, McKay FH. The availability and acquisition of modafinil on the internet. Drug Alcohol Rev. 2019;38(6):699–702.
   PubMed Web of Science ®Google Scholar
• Randall DC, Shneerson JM, Plaha KK, File SE. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol Clin Exp. 2003;18(3):163–173.
   PubMed Web of Science ®Google Scholar
• Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl). 2003;165(3):260–269.
   PubMed Web of Science ®Google Scholar
• Muller U, Steffenhagen N, Regenthal R, Bublak P. Effects of modafinil on working memory processes in humans. Psychopharmacology (Berl). 2004;177(1–2):161–169.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Yoon JH, Carter CS. Modafinil modulation of the default mode network. Psychopharmacology (Berl). 2011;215(1):23–31.
   PubMed Web of Science ®Google Scholar
• Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol Clin Exp. 2004;19(5):323–332.
   PubMed Web of Science ®Google Scholar
• Randall DC, Viswanath A, Bharania P, et al. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol. 2005;25(2):175–179.
   PubMed Web of Science ®Google Scholar
• Randall DC, Fleck NL, Shneerson JM, File SE. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav. 2004;77(3):547–555.
   PubMed Web of Science ®Google Scholar
• Cope ZA, Minassian A, Kreitner D, et al. Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Neuropharmacology. 2017;125:254–262.
   PubMed Web of Science ®Google Scholar
• Randall DC, Shneerson JM, File SE. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol Biochem Behav. 2005;82(1):133–139.
   PubMed Web of Science ®Google Scholar
• Winder-Rhodes SE, Chamberlain SR, Idris MI, Robbins TW, Sahakian BJ, Müller U. Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. J Psychopharmacol. 2010;24(11):1649–1657.
   PubMed Web of Science ®Google Scholar
• Muller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. 2013;64:490–495.
   PubMed Web of Science ®Google Scholar
• Rycroft N, Hutton SB, Clowry O, Groomsbridge C, Sierakowski A, Rusted JM. Non-cholinergic modulation of antisaccade performance: a modafinil-nicotine comparison. Psychopharmacology (Berl). 2007;195(2):245–253.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Mascayano F, Lips W, Painel A, Norambuena J, Madrid E. Effects of modafinil on attention performance, short-term memory and executive function in university students: a randomized trial. Medwave. 2015;15(5):e6166.
   PubMed Web of Science ®Google Scholar
• Baranski JV, Pigeau RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res. 1997;6(2):84–91.
   PubMed Web of Science ®Google Scholar
• Kredlow MA, Keshishian A, Oppenheimer S, Otto MW. The efficacy of modafinil as a cognitive enhancer: a systematic review and meta-analysis. Journal of Clinical Psychopharmacology. 2019;39(5):455–461.
   PubMed Web of Science ®Google Scholar
• Bellebaum C, Kuchinke L, Roser P. Modafinil alters decision making based on feedback history - a randomized placebo-controlled double blind study in humans. J Psychopharmacol. 2017;31(2):243–249.
   PubMed Web of Science ®Google Scholar
• Spiller HA, Hays HL, Aleguas A. Jr., Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 2013;27(7):531–543.
   PubMed Web of Science ®Google Scholar
• Carstairs SD, Urquhart A, Hoffman J, Clark RF, Cantrell FL. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol. 2010;6(3):307–310.
   PubMedGoogle Scholar
• Spiller HA, Borys D, Griffith JRK, et al. Toxicity from modafinil ingestion. Clin Toxicol (Phila). 2009;47(2):153–156.
   PubMed Web of Science ®Google Scholar
• Cairns R, Daniels B, Wood DA, Brett J. ADHD medication overdose and misuse: the NSW poisons information centre experience, 2004–2014. Med J Aust. 2016;204(4):154.
   PubMed Web of Science ®Google Scholar
• Neuman G, Shehadeh N, Pillar G. Unsuccessful suicide attempt of a 15 year old adolescent with ingestion of 5000 mg modafinil. J Clin Sleep Med. 2009;5(4):372–373.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120(1–3):135–141.
   PubMed Web of Science ®Google Scholar
• Şahan E, Bölükbaşı Ö. Modafinil intoxication induced persistent psychosis: case report. Psychiatria Danubina 2019;31(3):369–370.
   PubMed Web of Science ®Google Scholar
• Joos L, Docx L, Schmaal L, Sabbe BG, Dom G. [Modafinil in psychiatric disorders: the promising state reconsidered]. Tijdschr Psychiatr. 2010;52(11):763–773.
   PubMedGoogle Scholar
• Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol. 2012;27:e2012007.
   PubMedGoogle Scholar
• Danaher J. Should we use commitment contracts to regulate student use of cognitive enhancing drugs? Bioethics. 2016;30(8):568–578.
   PubMed Web of Science ®Google Scholar
• Lamkin M. Cognitive enhancements and the values of higher education. Health Care Anal. 2012;20(4):347–355.
   PubMed Web of Science ®Google Scholar
• Maier LJ, Haug S, Schaub MP. The importance of stress, self-efficacy, and self-medication for pharmacological neuroenhancement among employees and students. Drug Alcohol Depend. 2015;156:221–227.
   PubMed Web of Science ®Google Scholar
• Sattler S, Mehlkop G, Graeff P, Sauer C. Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Subst Abuse Treat Prev Policy. 2014;9(1):8.
   PubMedGoogle Scholar